NCT06706583

Brief Summary

Brief Summary: Open-label, cluster randomized, multicenter clinical trial to evaluate the clinical and ecological impact of a Primary Care ASP based on telematic educational interviews.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 22, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 26, 2024

Completed
5 days until next milestone

Study Start

First participant enrolled

December 1, 2024

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

November 26, 2024

Status Verified

November 1, 2024

Enrollment Period

1.3 years

First QC Date

November 22, 2024

Last Update Submit

November 22, 2024

Conditions

Keywords

Antimicrobial Stewardship Program (ASP)Primary CareTelemedicinePIRASOA

Outcome Measures

Primary Outcomes (1)

  • Total antimicrobial consumption

    Total antimicrobial antimicrobial will be measured using the recommended international standard, the Defined Daily Dose (DDD) per 1000 inhabitants per day. Predefined subgroup analyses will be conducted to assess the intervention\'s effect on the primary outcome based on: patient age, geneder, and socioeconomic level.

    Monthly over a 36-month period

Secondary Outcomes (3)

  • Adequacy of antimicrobial prescriptions

    Prevalence surveys will be performed at months +0, +7 and +15.

  • Incidence density of hospitalizations due to infections

    Monthly, over a 36-month period.

  • Incidence density of resistant Enterobacterales in urine cultures

    Monthly, over a 36-month period.

Study Arms (2)

Enhanced education arm

EXPERIMENTAL

Telematic educational interviews are added to standard PIRASOA training

Behavioral: Telematic educational interviews + standard training

Standard education arm

ACTIVE COMPARATOR

Only standard PIRASOA training is provided

Behavioral: Standard training

Interventions

Physicians attending at healthcare centers in the experimental arm will receive periodic telematic educational interviews in which an Infectious Diseases consultant will provide practical training on the appropriate use of antibiotics through the review of one of the physician´s randomly chosen antibiotic prescription, according to a structured brief interview. In addition to this, each of these centres will continue carrying out the already established activities of the Regional ASP (PIRASOA).

Enhanced education arm

Primary Care Health Centers assigned to the control group will receive standard educational activities designated by the current Regional ASP (PIRASOA).

Standard education arm

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • a) Primary Care centres within the reference area of the University Hospital Virgen del Rocío.

You may not qualify if:

  • Emergency departments.
  • Odontology offices.
  • DDD per Health centre less than 5.78

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitario Virgen del Rocío

Seville, 41013, Spain

RECRUITING

MeSH Terms

Conditions

Community-Acquired Infections

Condition Hierarchy (Ancestors)

Infections

Study Officials

  • José Miguel Cisneros Herreros, MD-PhD

    Hospitales Universitarios Virgen del Rocío

    STUDY DIRECTOR

Central Study Contacts

Clara M Rosso Fernández, MD-PhD

CONTACT

Jose Molina Gil-Bermejo, MD-PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Cluster randomized clinical trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 22, 2024

First Posted

November 26, 2024

Study Start

December 1, 2024

Primary Completion

March 31, 2026

Study Completion

March 31, 2026

Last Updated

November 26, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will share

Locations